IP Library Granted Patent US 9,220,758
Granted Patent B2
US 9,220,758 · App. 14/046,501 · Granted Dec 29, 2015

Calcitonin products and therapies for treating inflammatory or degenerative diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,220,758
App. No.
14/046,501
Granted
Dec 29, 2015
Kind
B2
Abstract

Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a cyclooxygenase-2 (COX-2) inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject.

Claims (13)

1. A method for treating osteoarthritis in a subject in need thereof comprising: administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a tetracycline antibiotic, to the subject.

2. The method of claim 1 , wherein the calcitonin is selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin and elcatonin.

3. The method of claim 1 , wherein the calcitonin is salmon calcitonin.

4. The method of claim 3 , wherein the subject is a human.

5. The method of claim 1 , wherein the calcitonin and the tetracycline antibiotic are each administered to the subject orally.

6. The method of claim 1 , wherein the tetracycline antibiotic is doxycycline.

7. The method of claim 6 , wherein the subject is a human.

8. The method of claim 1 , wherein the calcitonin and the tetracycline antibiotic are administered as a single pharmaceutical composition.

9. The method of claim 1 , wherein the calcitonin and the tetracycline antibiotic are administered separately.

10. The method of claim 1 , wherein the tetracycline antibiotic is administered at a dosage no higher than 90% of the normal dosage for the tetracycline antibiotic when administered alone for the treatment of osteoarthritis.

11. The method of claim 1 , wherein the subject is a human.

12. The method of claim 1 , wherein the calcitonin is salmon calcitonin and the tetracycline antibiotic is doxycycline.

13. A method for treating osteoarthritis in a human subject in need thereof comprising: administering a therapeutically effective amount of salmon calcitonin, in free or salt form, to the human subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of doxycycline to the human subject.

Assignments (7)
SECURITY INTEREST Recorded Sep 26, 2024
From: TRIS PHARMA, INC.; PARK THERAPEUTICS, INC.
To: PROVIDENT BANK
Reel/Frame 069065/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: TAURUS DEVELOPMENT COMPANY LLC
To: PARK THERAPEUTICS, INC.
Reel/Frame 062287/0841 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2018
From: TARSA THERAPEUTICS, INC.
To: TAURUS DEVELOPMENT COMPANY LLC
Reel/Frame 047580/0917 →
SECURITY INTEREST Recorded Jun 30, 2016
From: TARSA THERAPEUTICS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 039056/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: MEHTA, NOZER M.; GILLIGAN, JAMES P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 038350/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: UNIGENE LABORATORIES, INC.
To: UGP THERAPEUTICS, INC.
Reel/Frame 038350/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: UGP THERAPEUTICS, INC.
To: TARSA THERAPEUTICS, INC.
Reel/Frame 038350/0467 →